ERBB2 and female reproductive system neoplasm: Consistent with this view, our group has previously demonstrated that ADCs targeting HER2 are remarkably more effective both in vitro and in vivo against gynecologic tumor models when compared to the unconjugated humanized monoclonal antibody targeting the same biomarker [12,13].